Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) P/B ratio
As of 16 October 2026, Biogen Inc. (BIIB) trades at a P/B ratio of 1.8×. Over the past ten years it has ranged from 1.0× (April 2025) to 10.4× (March 2015); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 5.0× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.4× | 6.02% |
| FY2024 | 1.3× | (49.11%) |
| FY2023 | 2.6× | (11.54%) |
| FY2022 | 3.0× | (9.35%) |
| FY2021 | 3.3× | (11.47%) |
| FY2020 | 3.7× | (11.42%) |
| FY2019 | 4.2× | (12.03%) |
| FY2018 | 4.7× | (16.10%) |
| FY2017 | 5.6× | 7.36% |
| FY2016 | 5.3× | (30.32%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 1.7× | 17.02% |
| Mar 2026 | 1.4× | 2.45% |
| Dec 2025 | 1.4× | 25.21% |
| Sep 2025 | 1.1× | 8.10% |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| SNY Sanofi compare | 1.2× |
| BIIB Biogen Inc. | 1.8× |
| PFE Pfizer Inc. compare | 2.0× |
| GSK GSK PLC Sponsored ADR compare | 4.3× |
| NVO Novo Nordisk A/S compare | 5.0× |
| AZN AstraZeneca PLC compare | 5.1× |
| BMY Bristol Myers Squibb Company compare | 5.5× |
| GILD Gilead Sciences, Inc. compare | 16.5× |
| AMGN Amgen Inc. compare | 20.0× |
| Drug Manufacturers General industry median | 5.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement